UNSPSC 51111646: Nelarabine

This classification denotes a purine antagonist with the molecular formula C11H15N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 60158CV180, chemically known as 9h-purin-2-amine, 9beta-d-arabinofuranosyl-6-methyl- but generally known as nelarabine, which bears US NIH Compound Identifier 151121. European Medicines Agency schedules Nelarabine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09188MIG.

World Health Organization schedules nelarabine in its Anatomical Therapeutic Chemical (ATC) Classification. As of Q4 2014, NELARABINE remains the US FDA Preferred Term for this commodity. Nelarabine bears US NLM identifiers UMLS ID C0907349 and NCI Concept Code C1704. SMILES: COC1=NC(=NC2=C1N=CN2C3C(C(C(O3)CO)O)O)N..

UNSPSC 51111646 Nelarabine, a Commodity code, covers a specific pharmaceutical product — a chemotherapy drug used in leukemia treatment — that state and local health agencies acquire through pharmacy benefit programs and direct contracting arrangements. State and local purchasing of nelarabine typically flows through Medicaid programs, state employee health plans, and corrections systems, though the code sees limited direct solicitation activity. Issuing bodies are primarily state health and human services departments, which manage prescription drug procurement either through pharmacy benefit managers or, increasingly, through direct-to-manufacturer arrangements that bypass intermediaries to negotiate net pricing and outcomes-based agreements.

The most recent activity centers on Texas Health and Human Services Commission's Request for Information (RFI) HHS0017013, posted April 3, 2026, which sought vendor capabilities for implementing a Therapeutic Pharmacy Initiative (TPI) Direct-to-Manufacturer Prescriptions program. The RFI explores how state agencies and self-insured employee health plans can establish direct relationships with pharmaceutical manufacturers, including vendors' experience with negotiated net pricing models and value-based payment structures. The exploratory nature of this RFI indicates the state is gathering market intelligence before issuing a formal Request for Proposal; no award values, budget allocations, or set-aside designations are identified at this stage. This code shows limited recent solicitation frequency — single-drug commodity codes in pharmacy procurement typically generate activity only when states restructure their drug-sourcing strategy or explore alternative contracting models, as Texas HHS is currently doing.